PMX-53 is a peptidic C5aR antagonist and has proven to be advantageous in experimental animal studies for neurodegenerative diseases, rheumatoid arthritis, ischemia/reperfusion and inflammatory bowel disease (102, 166, 167) . It is currently being evaluated in clinical trials, but a recent study in humans failed to show significant effects on synovial inflammation (168) .